Stefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, Ludovic Evesque, Denis Smith, Nicolas Badet, Emmanuelle Samalin, Daniel Lopez-Trabada Ataz, Aurelie Parzy, Jérôme Desramé, Nabil Baba Hamed, Bruno Buecher, David Tougeron, Olivier Bouché, Laetitia Dahan, Benoist Chibaudel, Farid El Hajbi, Laurent Mineur, Olivier Dubreuil, Meher Ben Abdelghani, Solange Pecout, Frederic Bibeau, Michael Herfs, Marie-Line Garcia, Aurelia Meurisse, Dewi Vernerey, Julien Taïeb, Christophe Borg
BACKGROUND: The modified docetaxel, cisplatin, and fluorouracil (mDCF) regimen has shown efficacy and safety as first-line treatment for advanced squamous cell carcinoma of the anus, making it a standard regimen. Inhibitors of programmed cell death protein 1 and its ligand, such as pembrolizumab, nivolumab, retifanlimab, avelumab, and atezolizumab, have shown some antitumour activity as monotherapy in advanced squamous cell carcinoma of the anus that is refractory to chemotherapy. This phase 2 study evaluated the combination of mDCF and atezolizumab as first-line treatment in advanced squamous cell carcinoma of the anus...
April 2024: Lancet Oncology